A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical ...

In the first head-to-head test, people using Eli Lilly’s Zepbound lost just over 50 pounds while those using competitor Novo ...

W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

Eli Lilly shares rose nearly 1.6% on Wednesday morning to three-week highs after the company unveiled promising results from ...

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...

Eli Lilly's Zepbound has outperformed Novo Nordisk's Wegovy in a pivotal clinical trial, marking a significant milestone in ...

Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative ...

About one-third of US adults without diabetes who are eligible for weight loss treatment with GLP-1 receptor agonists and GLP-1/GIP receptor agonists meet exclusion criteria for clinical trials.